A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Effectiveness of a Phosphodiesterase 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated With Radiotherapy for Prostate Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tadalafil (Primary)
- Indications Erectile dysfunction
- Focus Therapeutic Use
Most Recent Events
- 14 Feb 2018 Biomarkers information updated
- 02 Apr 2014 Results published in the JAMA: the Journal of the American Medical Association.
- 04 Jun 2013 Preliminary results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.